LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

ELISA Kit Accurately Detects Bioactive Hepcidin Levels

By LabMedica International staff writers
Posted on 17 Aug 2015
Print article
Image: The DRG Hepcidin 25 HS enzyme-linked immunosorbent assay (ELISA) kit (Photo courtesy of DRG International).
Image: The DRG Hepcidin 25 HS enzyme-linked immunosorbent assay (ELISA) kit (Photo courtesy of DRG International).
An enzyme-linked immunosorbent assay (ELISA) kit has been introduced that accurately detects bioactive hepcidin levels as an additional marker to aid in identifying a variety of disorders.

Hepcidin has been identified as a factor in regulating the amount of iron in humans and unbalanced iron level can lead to many common medical conditions including anemia and iron overload disease, and can occur in chronic kidney disease, inflammation, or diabetes mellitus.

The new Hepcidin 25 (bioactive) HS ELISA kit has an analytical sensitivity of 0.153 ng/mL, with a measuring range of 0 81 ng/mL to 153 ng/mL. Serum or plasma samples can be assessed and the total incubation time is less than two hours. The ELISA is user-friendly as no shaker and no assay buffer is required, and all reagents except wash solution are ready-to-use.

The new DRG Hepcidin 25 (bioactive) HS (High Sensitive) ELISA Kit is manufactured by DRG International (Springfield Township, NJ, USA) and is more sensitive that their previous product for measuring hepcidin. The DRG Hepcidin 25 (bioactive) HS ELISA Kit is available worldwide, providing a simple, fast and accurate method to test hepcidin levels. The measurement results of this kit offer more information to help treat medical issues including iron deficiency diseases, which are some of the most common diseases worldwide. The ELISA kit is Conformité Européenne (CE) marked.

Cyril E. Geacintov, PhD, founder, president and CEO of DRG International, said, “We at DRG International saw the need for an accurate and easy to use hepcidin testing kit and are encouraged by the great success that our customers have seen using the product. This kit is an important step to meet the rapidly growing worldwide interest in hepcidin testing and the applications of that testing in the health and wellness community.”

The new Hepcidin ELISA kit was showcased at the American Association for Clinical Chemistry (AACC) annual meeting held from July 27-30, 2015, in Atlanta (Georgia, USA).

Related Links:

DRG International


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more